Semax (5mg Vial)
Semax is a peptide studied for its broad activity in the brain, supporting mental performance and neuronal protection:
Enhanced focus and memory: increases memory retention and concentration capacity, ideal for high mental performance.
Advanced neuroprotection: helps protect neurones against oxidative stress and ischaemic damage, supporting long-term brain health.
BDNF support: stimulates the production of BDNF (Brain-Derived Neurotrophic Factor), essential for synaptic plasticity.
Key Benefits
Focus and mental clarity during intense, high-demand routines.
More stable mood and motivation (support for mental “drive”).
Memory and learning (support for cognitive performance).
Mental resilience during periods of stress and fatigue.
SKU:
Category:
Tags:
Semax is a peptide studied for its broad activity in the brain, supporting mental performance and neuronal protection:
Enhanced focus and memory: increases memory retention and concentration capacity, ideal for high mental performance.
Advanced neuroprotection: helps protect neurones against oxidative stress and ischaemic damage, supporting long-term brain health.
BDNF support: stimulates the production of BDNF (Brain-Derived Neurotrophic Factor), essential for synaptic plasticity.
Key Benefits
Focus and mental clarity during intense, high-demand routines.
More stable mood and motivation (support for mental “drive”).
Memory and learning (support for cognitive performance).
Mental resilience during periods of stress and fatigue.
Technical Details
Item Weight
Product Dimensions
Item model number
Item Package Quantity
Number of Handles
Batteries Required?
RECONSTITUTION, DOSING AND STORAGE OF PEPTIDES IN A VIAL
(General guidance – not peptide-specific)
1. INTRODUCTION
Peptides supplied in a vial (a glass vial containing lyophilised powder) are not ready for immediate use.
Before administration, it is mandatory to carry out reconstitution, which is the process of converting the lyophilised powder into a sterile liquid solution.
Correct reconstitution is essential to ensure:
Safe use
Peptide stability
Accurate dosing
Protocol effectiveness
⚠️ Incorrect preparation may result in inaccurate dosing and reduced effectiveness.
2. REQUIRED MATERIALS
Vial containing the lyophilised peptide
Bacteriostatic Water
Contains approximately 0.9% benzyl alcohol
Helps inhibit bacterial growth
Insulin syringe (100 units = 1 mL)
Sterile needle
Clean, hygienic environment
3. WHAT RECONSTITUTION IS
Reconstitution is the controlled addition of bacteriostatic water to the lyophilised powder, creating a liquid solution suitable for subcutaneous use.
4. GENERAL RULE FOR CALCULATING CONCENTRATION
Basic formula:
Amount of peptide (mg) ÷ Volume of water (mL) = Concentration (mg/mL)
This concentration is used to calculate the correct dose in the syringe.
5. CORRECT RECONSTITUTION TECHNIQUE
⚠️ IMPORTANT: PEPTIDES ARE FRAGILE MOLECULES
Recommended procedure:
- Draw the desired volume of bacteriostatic water into the syringe.
- Insert the needle into the vial.
- Allow the water to run slowly down the inner wall of the vial.
- Do not direct the stream straight onto the powder.
- Do not shake the vial.
Gently roll the vial between your fingers until fully dissolved.
**Vigorous shaking may cause peptide degradation.
6. CONVERSION FOR AN INSULIN SYRINGE
1 mL = 100 units
The amount of peptide per unit depends on the final concentration after reconstitution.
Always calculate dosing based on the concentration (mg/mL).
7. STORAGE AFTER RECONSTITUTION
Keep refrigerated between 2°C and 8°C
Do not freeze
Keep the vial tightly sealed
Protect from light, especially for photosensitive peptides
8. FINAL CONSIDERATIONS
- Always follow the correct preparation technique
- Use bacteriostatic water only
- Maintain strict accuracy in dose calculations
- Use should be carried out under professional supervision
Recommended Dose
-
Standard dose: 100–500 mcg per day
-
Focus protocol: 300 mcg first thing in the morning
How to Use
Step 1 — Reconstitution (5 mg vial)
Vial: 5 mg (5,000 mcg)
Diluent: Bacteriostatic Water
Syringe: U-100 insulin syringe (1 mL = 100 IU)
Add 5 mL of bacteriostatic water into the vial, following the correct handling and reconstitution guidelines.
(Insert your reconstitution care guide link here.)
Final Concentration
After reconstitution, the vial contains:
-
5,000 mcg in 5 mL
-
Final concentration: 1,000 mcg/mL
Quick Conversions
Volume to mcg
-
1.0 mL = 1,000 mcg
-
0.1 mL = 100 mcg
-
0.3 mL = 300 mcg
-
0.5 mL = 500 mcg
U-100 Syringe (1 mL = 100 IU)
-
100 mcg = 0.1 mL = 10 IU
-
300 mcg = 0.3 mL = 30 IU
-
500 mcg = 0.5 mL = 50 IU
Related Products
Retatrutide (4 x 10mg Vial)
Retatrutide is a triple agonist of GLP-1, GIP, and glucagon. This combination works in an integrated manner to reduce appetite and increase satiety, improve glycaemic homeostasis, and promote greater energy expenditure/thermogenesis via activity at the glucagon receptor.
This product is supplied as a pack of 4 vials, each containing 10 mg.
Key Benefits
-
Marked reduction in body weight in clinical studies, with high-impact results in obesity.
-
Improved glycaemic control and cardiometabolic markers (e.g., inflammatory lipids and blood pressure reported in readouts).
-
Reduced liver fat and improvements associated with metabolic liver disease (MASLD/MASH) in a Phase 2a study.
-
Quality of weight loss (body composition): evidence suggests a greater reduction in fat mass, without a disproportionate increase in lean mass loss, in body-composition sub-studies.
Tirzepatide (4 x 15mg Vial)
Tirzepatide is a dual agonist of GIP and GLP-1 receptors, acting in an integrated way across incretin pathways. It increases insulin secretion in a glucose-dependent manner and improves glycaemic regulation (reducing peaks and variability). It also acts on appetite/satiety centres, contributing to reduced food intake.
This product is supplied as a pack of 4 vials, each containing 15 mg.
Key Benefits
-
Significant reduction in body weight in studies involving people with obesity/overweight (results depend on dose, duration, and adherence).
-
Robust improvement in glycaemic control (HbA1c) in people with type 2 diabetes, with dose-dependent reductions observed in clinical trials.
-
Cardiometabolic improvements associated with weight loss and incretin pathway activity.
-
Maintenance of weight loss with continued treatment, demonstrating sustained outcomes when use is maintained within protocol (in maintenance trials).
Tirzepatide (60mg)
Intelligent metabolic regulation for consistent weight loss.
Tirzepatide is a dual agonist of GIP and GLP-1 receptors, acting in an integrated way across incretin pathways.It increases insulin secretion in a glucose-dependent manner and improves glycaemic regulation (reducing peaks and variability).
It acts on appetite/satiety centres, helping to reduce food intake and supporting adherence to body recomposition strategies.
Key Benefits
- Significant reduction in body weight in studies involving people with obesity/overweight (results depend on dose, duration, and adherence).
- Robust improvement in glycaemic control (HbA1c) in people with type 2 diabetes, with dose-dependent reductions observed in clinical trials.
- Cardiometabolic improvements associated with weight loss and incretin pathway activity.
- Maintenance of weight loss with continued treatment, demonstrating sustained outcomes when use is maintained within protocol (in maintenance trials).
Retatrutide (40mg)
Mechanism of Action
Retatrutide is a triple agonist of GLP-1, GIP, and glucagon receptors. This combination works in an integrated manner to reduce appetite and increase satiety, improve glycaemic homeostasis, and promote greater energy expenditure/thermogenesis via activity at the glucagon receptor.
Key Benefits
– Marked reduction in body weight in clinical studies, with high-impact results in obesity.
– Improved glycaemic control and cardiometabolic markers (e.g., inflammatory lipids and blood pressure reported in readouts).
– Reduction in liver fat and improvements associated with metabolic liver disease (MASLD/MASH) in a Phase 2a study.
– Quality of weight loss (body composition): evidence suggests a greater reduction in fat mass, without a disproportionate increase in lean mass loss, in body-composition sub-studies.
– Tolerability profile consistent with the incretin class, with gastrointestinal events most commonly reported in studies (e.g., nausea, diarrhoea, and constipation).
